The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity - A systematic review

Olchowy, Cyprian; Cebulski, Kamil; Łasecki, Mateusz; Chaber, Radosław; Olchowy, Anna; Kałwak, Krzysztof; Zaleska-Dorobisz, Urszula

doi:10.1371/journal.pone.0171704

Cited by 166 publications

(122 citation statements)

References 48 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…Costs, time required to perform the study, gadolinium-based contrast media potential risk in patients with impaired renal function and its accumulation in the central nervous system represent the major drawbacks of DCE. [40] The value of bpMRI in the detection of PCa using 1.5T MRI with endorectal coil has been reported. [23,41] Recently, it has been demonstrated that the sensitivity of bpMRI at 3T without endorectal coil in the detection PCa is similar to that of mpMRI.…”

Section: Diffusion-weighted Imagingmentioning

confidence: 99%

Biparametric MRI of the prostate

Scialpi

D’Andrea

Martorana

et al. 2017

Turkish Journal of Urology

View full text Add to dashboard Cite

Biparametric Magnetic Resonance Imaging (bpMRI) of the prostate combining both morphologic T2-weighted imaging (T2WI) and diffusion-weighted imaging (DWI) is emerging as an alternative to multiparametric MRI (mpMRI) to detect, to localize and to guide prostatic targeted biopsy in patients with suspicious prostate cancer (PCa). BpMRI overcomes some limitations of mpMRI such as the costs, the time required to perform the study, the use of gadolinium-based contrast agents and the lack of a guidance for management of score 3 lesions equivocal for significant PCa. In our experience the optimal and similar clinical results of the bpMRI in comparison to mpMRI are essentially related to the DWI that we consider the dominant sequence for detection suspicious PCa both in transition and in peripheral zone. In clinical practice, the adoption of bpMRI standardized scoring system, indicating the likelihood to diagnose a clinically significant PCa and establishing the management of each suspicious category (from 1 to 4), could represent the rationale to simplify and to improve the current interpretation of mpMRI based on Prostate Imaging and Reporting Archiving Data System version 2 (PI-RADS v2). In this review article we report and describe the current knowledge about bpMRI in the detection of suspicious PCa and a simplified PI-RADS based on bpMRI for management of each suspicious PCa categories to facilitate the communication between radiologists and urologists.

show abstract

Section: Diffusion-weighted Imagingmentioning

confidence: 99%

Biparametric MRI of the prostate

Scialpi

D’Andrea

Martorana

et al. 2017

Turkish Journal of Urology

View full text Add to dashboard Cite

show abstract

“…Thus far, 15 out of 19 studies found a positive correlation between the number of administrations of a linear chelate and the measured signal intensity in the basal ganglia. At this moment, the association has not been demonstrated for the macrocyclic chelates [6,7]. The four contrast agents that the EMA has recommended suspending and/or restricting …”

Section: Evidence For Gadolinium Retentionmentioning

confidence: 92%

Gadolinium retention after administration of contrast agents based on linear chelators and the recommendations of the European Medicines Agency

2017

View full text Add to dashboard Cite

The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) earlier this year recommended to suspend some marketing authorisations for Gadolinium Containing Contrast Agents (GCCAs) based on linear chelators due to the potential risk of gadolinium retention in the human body. These recommendations have recently been re-evaluated by EMA's Committee for Medicinal Products for Human Use (CHMP), and confirmed the final opinion of the European Medicines Agency. This editorial provides an overview of the available GCCAs and summarises the recent evidence of gadolinium retention. Moreover, a critical appraisal of the strengths and limitations of the scientific evidence currently available on gadolinium retention is given. Key points • EMA recommended suspension of some EU marketing authorisations of four linear GCCAs. • Brain MRI findings indicating gadolinium retention have been confirmed by mass spectrometry.• Current scientific evidence for gadolinium retention has several methodological limitations.• No clear clinical evidence exists indicating that gadolinium retention causes neurotoxicity.• Long-term safety of GCCAs, however, remains unclear.

show abstract

“…A T1-weighted MRI acquired post GBCA injection is a part of the recommended MRI protocols for diagnosis and follow-up examinations of MS patients [3]. However, the use of GBCAs has been a recent topic of debate, primarily due to reports of Gd deposition in the brain [4,5]. Suggestions insisting on greater debate before GBCA administration has gained traction due to observed MRI signal changes in the brain tissues due to repeated GBCA administrations and other possible health issues [6].…”

Section: Introductionmentioning

confidence: 99%

Identification of Gadolinium Contrast Enhanced Regions in MS Lesions Using Brain Tissue Microstructure Information Obtained from Diffusion and T2 Relaxometry MRI

Chatterjee

Commowick

Afacan

et al. 2018

Medical Image Computing and Computer Assisted Intervention – MICCAI 2018

View full text Add to dashboard Cite

Identifying MS lesions in a patient which are undergoing active BBB breakdown is of critical importance for MS burden evaluation and treatment planning. However in non-contrast enhanced structural magnetic resonance imaging (MRI) the regions of the lesion undergoing active BBB breakdown cannot be distinguished from the other parts of the lesion. Hence gadolinium (Gd) contrast enhanced T1-weighted MR images are used for this task. However some side effects of Gd injection into patients have been increasingly reported recently. The BBB breakdown is reflected by the condition of tissue microstructure such as increased inflammation, presence of higher extra-cellular matter and debris. We thus propose a framework to predict enhancing regions in MS lesions using tissue microstructure information derived from T2 relaxometry and diffusion MRI (dMRI) multicompartment models. We show that combination of the dMRI and T2 relaxometry microstructure information can distinguish the Gd enhancing lesion regions from the other regions in MS lesions.

show abstract

The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity - A systematic review

Cited by 166 publications

References 48 publications

Biparametric MRI of the prostate

Biparametric MRI of the prostate

Gadolinium retention after administration of contrast agents based on linear chelators and the recommendations of the European Medicines Agency

Identification of Gadolinium Contrast Enhanced Regions in MS Lesions Using Brain Tissue Microstructure Information Obtained from Diffusion and T2 Relaxometry MRI

Contact Info

Product

Resources

About